Medullary thyroid carcinoma

• Titel: Medullary thyroid carcinoma
• Titelzusatz: biology, management, and treatment of sporadic and hereditary MTC
• Mitwirkende: Raue, Friedhelm [HerausgeberIn]
• Mitwirkende: Frank-Raue, Karin [HerausgeberIn]
• Verf.angabe: edited by Friedhelm Raue, Karin Frank-Raue
• Ausgabe: 2nd ed. 2025.
• Verlagsort: Cham
• Verlagsort: Cham
• Verlag: Springer Nature Switzerland
• Verlag: Imprint: Springer
• E-Jahr: 2025
• Jahr: 2025.
• Jahr: 2025.
• Umfang: 1 Online-Ressource (XVI, 307 p. 48 illus., 30 illus. in color.)
• Gesamttitel/Reihe: Recent Results in Cancer Research ; 223
• ISBN: 978-3-031-80396-3
• DOI: doi:10.1007/978-3-031-80396-3
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• K10plus-PPN: 192050303X
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext
• Lokale URL UB: Bibliothek der Medizinischen Fakultät Mannheim der Universität Heidelberg
• Bibliothek/Idn: UW / m4692501340
• Lokale URL Inst.: Zum Volltext

Abstract

What is new? -- Thyroid C-Cell Biology and Oncogenic Transformation -- Histopathology of C cells and medullary thyroid carcinoma -- Epidemiology and clinical presentation of Medullary Thyroid Carcinoma -- Medullary thyroid carcinoma: Imaging -- Calcitonin as a Biomarker for Medullary Thyroid Carcinoma -- Hereditary Medullary Thyroid Cancer, Genotype phenotype correlation -- Pheochromocytomas in Multiple Endocrine Neoplasia type 2 -- Primary hyperparathyroidism in Multiple Endocrine Neoplasia 2 Syndrome -- Surgical treatment of medullary thyroid carcinoma -- Long term follow up in medullary thyroid carcinoma -- Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.

Abstract

After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists. Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.